Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The antibody was designed and developed at Abzena’s Cambridge, UK,
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Subscribe To Our Newsletter & Stay Updated
